Article
Journal of Medicinal Chemistry, 2011, Vol. 54, No. 4 1031
(R,R)- and (S,S)-7, 16, 17 and 19. This material is available free
derivative PB28, a σ2 agonist and σ1 antagonist receptor inhibits
cell growth, modulates P-glycoprotein, and synergizes with anthra-
cyclines in breast cancer. Mol. Cancer Ther. 2006, 5, 1807–1816.
(21) Hashimoto, K.; Ishiwata, K. Sigma receptor ligands: possible
application as therapeutic drugs and as radiopharmaceuticals.
Curr. Pharm. Des. 2006, 12, 3857–3876.
(22) Mach, R. H; Wheeler, K. T. Development of molecular probes for
imaging sigma-2 receptors in vitro and in vivo. Cent. Nerv. Syst.
Agents Med. Chem. 2009, 9, 230–245.
(23) Mach, R. H.; Huang, Y.; Freeman, R. A.; Wu, L.; Vangveravong,
S.; Luedtke, R. R. Conformationally-flexible benzamide analogues
as dopamine D3 and σ2 receptor ligands. Bioorg. Med. Chem. 2004,
14, 195–202.
(24) Berardi, F.; Ferorelli, S.; Abate, C.; Colabufo, N. A.; Contino, M.;
Perrone, R.; Tortorella, V. 4-(Tetralin-1-yl)- and 4-(naphthalen-1-yl)-
alkyl derivatives of 1-cyclohexylpiperazine as σ receptor ligands with
agonist σ2 activity. J. Med. Chem. 2004, 47, 2308–2317.
(25) Kassiou, M.; Robert, F.; Dannals, R. F.; Liu, X.; Wong, D. F.;
Ravert, H. T.; Scheffel, U. A. Synthesis and in vivo evaluation of a
new PET radioligand for studying sigma-2 receptors. Bioorg. Med.
Chem. 2005, 13, 3623–3626.
(26) Abate, C.; Mosier, P. D.; Berardi, F.; Glennon, R. A. A structure-
affinity and comparative molecular field analysis of sigma-2 (σ2)
receptor ligands. Cent. Nerv. Syst. Agents Med. Chem. 2009, 9, 246–
257.
(27) Abate, C.; Berardi, F.; Colabufo, N. A.; Ferorelli, S.; Perrone, R.
Tritium radiolabeling of [3H]-1-cyclohexyl-4-[3-(5-methoxy-1,2,3,
4,-tetrahydronaphthalen-1-yl)-n-propyl]piperazine ([3H]-PB28), as
a potent sigma-2 receptor ligand. WO/2009/104058.
(28) Meyer, M. D.; Hancock, A. A.; Tietje, K.; Sippy, K. B.; Prasad, R.;
Stout, D. M.; Arendsen, D. L.; Donner, B. G.; Carroll, W. A.
Structure-activity studies for novel series of N-(arylethyl)-N-
(1,2,3,4-tetrahydronaphthalen-1-yl-methyl)-N-methylamines pos-
sessing dual 5-HT uptake inhibiting and R2-antagonistic activities.
J. Med. Chem. 1997, 40, 1049–1062.
(29) Gutman, A. L.; Etinger, M.; Nisnevich, G.; Polyak, F. Stereo- and
regioselectivity in asymmetric synthesis of R-amino substituted benzo-
cyclic compounds. Tetrahedron: Asymmetry 1998, 9, 4369–4379.
(30) Martin, Y. C.; Jarboe, C. H.; Krause, R. A.; Lynn, K. R.; Dunnigan,
D.; Holland, J. B. Potential anti-Parkinson drugs designed by receptor
mapping. J. Med. Chem. 1973, 16, 147–150.
(31) Perrone, R.; Berardi, F.; Colabufo, N. A.; Leopoldo, M.; Tortorella,
V. 1-Aryl-4-[(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)alkyl]piper-
azines and their analogues: influence of the stereochemistry of the
tetrahydronaphthalen-1-yl nucleus on 5-HT1A receptor affinity and
selectivity versus R1 and D2 receptors. 5. J. Med. Chem. 1999, 42, 490–
496.
(32) Ferraz, H. M. C.; Bianco, G. G.; Teixeira, C. C.; Andrade, L. H.;
Porto, A. L. M. Enzymatic resolution of R-tetralols by CALB-
catalyzed acetylation. Tetrahedron: Asymmetry 2007, 18, 1070–
1076.
(33) Fujii, A.; Hashiguchi, S.; Uematsu, N.; Ikariya, T.; Noyori, R.
Ruthenium (II)-catalyzed asymmetric transfer hydrogenation of
ketones using a formic acid-triethylamine mixture. J. Am. Chem.
Soc. 1996, 118, 2521–2522.
(34) Siddaiah, V.; Rao, C. V.; Venkateswarlu, S.; Krishnaraju, A. V.;
Subbaraju, G. V. Synthesis, stereochemical assignments, and bio-
logical activities of homoisoflavonoids. Bioorg. Med. Chem. 2006,
14, 2545–2551.
(35) Perrone, R.; Berardi, F.; Colabufo, N. A.; Leopoldo, M.; Tortorella,
V.; Fiorentini, F.; Olgiati, V.; Ghiglieri, A.; Govoni, S. High affinity
and selectivity on 5-HT1A receptor of 1-aryl-4-[(1-tetralin)alkyl]-
piperazines. 2. J. Med. Chem. 1995, 38, 942–949.
(36) H. Ishii, H.; Hanaoka, T.; Asaka, T.; Harada, Y.; Ikeda, N.
Oxidation with Fremy’s salt;VIII: Peri-effect of a group located
at the C5 position of 1-naphthol and related compounds. Tetra-
hedron 1976, 32, 2693–2698.
(37) Kamila, S.; Mukherjee, C.; Mondal, S. S.; De, A. Application of
directed metallation in synthesis. Part 3: Studies in the synthesis of
(()-semivioxanthin and its analogues. Tetrahedron 2003, 59, 1339–
1348.
(38) Glennon, R. A. Pharmacophore identification for sigma-1 (σ1)
receptor binding: application of the “deconstruction-recons-
truction-elaboration” approach. Mini-Rev. Med. Chem. 2005, 5,
927–940.
References
(1) Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppler, R. E.;
Gilbert, P. E. The effect of morphine- and nalorphine-like drugs in
the nondependent and morphine-dependent chronic spinal dog.
J. Pharmacol. Exp. Ther. 1976, 197, 517–532.
(2) Hanner, M.; Moebius, F. F.; Flandorfer, A.; Knaus, H. G.;
Striessnig, J. M.; Kempner, E.; Glossmann, H. Purification,
molecular cloning, and expression of the mammalian sigma1-
binding site. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8072–8077.
(3) Tsai, S.-Y.; Hayashi, T.; Mori, T.; Su, T-P. Sigma-1 receptor
chaperones and diseases. Cent. Nerv. Syst. Agents Med. Chem.
2009, 9, 184–189.
(4) Hayashi, T.; Su, T-P. σ1 Receptors (σ1 binding sites) form raft-like
microdomains and target lipid droplets on the endoplasmic reticu-
lum: roles in endoplasmic reticulum lipid compartmentalization
and export. J. Pharmacol. Exp. Ther. 2003, 306, 718–725.
(5) Palmer, C. P.; Mahen, R.; Schnell, E.; Djamgoz, M. B. A.; Aydar,
E. Sigma-1 receptors bind cholesterol and remodel lipid rafts in
breast cancer cell lines. Cancer Res. 2007, 67, 11166–11175.
(6) Cobos, E. J.; Entrena, J. M.; Nieto, F. R.; Cendan, C. M.; Del Pozo,
E. Pharmacology and therapeutic potential of sigma1 receptor
ligands. Curr. Neuropharmacol. 2008, 6, 344–366.
(7) Skuza, G. Potential antidepressant activity of sigma ligands.
Pol. J. Pharm. 2003, 55, 923–934.
(8) Skuza, G.; Rogoz, Z. Effect of BD1047, a sigma1 receptor antago-
nist, in the animal models predictive of antipsychotic activity.
Pharmacol. Rep. 2006, 58, 626–635.
(9) Jansen, K. L.; Faull, R. L.; Storey, P.; Leslie, R. A. Loss of sigma
binding sites in the CA1 area of the anterior hippocampus in
Alzheimer’s disease correlates with CA1 pyramidal cell loss. Brain
Res. 1993, 623, 299–302.
(10) Mishina, M.; Ishiwata, K.; Ishii, K.; Kitamura, S.; Kimura, Y.;
Kawamura, K.; Oda, K.; Sasaki, T.; Sakayori, O.; Hamamoto, M.;
Kobayashi, S.; Katayama, Y. Function of sigma1 receptors in
Parkinson’s disease. Acta Neurol. Scand. 2005, 112, 103–107.
(11) Mishina, M.; Ohyama, M.; Ishii, K.; Kitamura, S.; Kimura, Y.;
Oda, K.; Kawamura, K.; Sasaki, T.; Kobayashi, S.; Katayama, Y.;
Ishiwata, K. Low density of sigma1 receptors in early Alzheimer’s
disease. Ann. Nucl. Med. 2008, 22, 151–56.
(12) Matsumoto, R. R.; Gilmore, D. L.; Pouw, B.; Bowen, W. D.;
Williams, W.; Kausar, A.; Coop, A. Novel analogs of the σ receptor
ligand BD1008 attenuate cocaine induced toxicity in mice. Eur.
J. Pharmacol. 2004, 492, 21–26.
(13) Colabufo, N. A.; Berardi, F.; Abate, C.; Contino, M.; Niso, M.;
Perrone, R. Is the σ2 receptor a histone binding protein? J. Med.
Chem. 2006, 49, 4153–4158.
(14) Abate, C.; Elenewski, J.; Niso, M.; Berardi, F.; Colabufo, N. A.;
Azzariti, A.; Perrone, R.; Glennon, R. A. Interaction of the σ2
receptor ligand PB28 with the human nucleosome: computational
and experimental probes of interaction with the H2A/H2B dimer.
ChemMedChem 2010, 5, 268–273.
(15) Zeng, C.; Vangveravong, S.; Xu, J.; Chang, K. C.; Hotchkiss, R. S.;
Wheeler, K. T.; Shen, D.; Zhuang, Z-P.; Kung, H. F.; Mach, R. H.
Subcellular localization of sigma-2 receptors in breast cancer cells
using two-photon and confocal microscopy. Cancer Res. 2007, 67,
6708–6716.
(16) Berardi, F.; Abate, C.; Ferorelli, S.; Colabufo, N. A.; Perrone, R.
1-Cyclohexylpiperazine and 3,3-dimethylpiperidine derivatives as
sigma-1 (σ1) and sigma-2 (σ2) receptor ligands: a review. Cent.
Nerv. Syst. Agents Med. Chem. 2009, 9, 205–219.
(17) Tu, Z.; Xu, J.; Jones, L. A.; Li, S.; Dumsdorf, C.; Vangveravong, S.;
Chen, D.; Wheeler, K. T.; Welch, M. J.; Mach, R. H. Fluorine-18
labeled benzamide analogs for imaging the sigma-2 receptor status
of solid tumors with positron emission tomography. J. Med. Chem.
2007, 50, 3194–3204.
(18) Kashiwagi, H.; McDunn, J. E.; Simon, P. O.; Goedegebuure, P. S.;
Xu, J.; Jones, L.; Chang, K.; Johnston, F.; Trinkaus, K.; Hotchkiss,
R. S.; Mach, R. H.; Hawkins, W. G. Selective sigma-2 ligands
preferentially bind to pancreatic adenocarcinomas: applications in
diagnostic imaging and therapy. Mol. Cancer 2007, 6, 48, doi: 10.1186/
1476-4598-6-48.
(19) Kashiwagi, H.; McDunn, J. E.; Simon, P. O.; Goedegebuure, P. S.;
Vangveravong, S.; Chang, K.; Hotchkiss, R. S.; Mach, R. H.;
Hawkins, W. G. Sigma-2 receptor ligands potentiate chemothera-
pies and improve survival in models of pancreatic adenocarcinoma.
J. Transl. Med. 2009, 7, 24, doi:10.1186/1479-5876-7-24.
(20) Azzariti, A.; Colabufo, N. A.; Berardi, F.; Porcelli, L.; Niso, M.;
Simone, M. G.; Perrone, R.; Paradiso, A. Cyclohexylpiperazine
(39) Waterhouse, R. N. Determination of lipophilicity and its use as a
predictor of blood-brain barrier penetration of molecular imaging
agents. Mol. Imaging Biol. 2003, 5, 376–389.
(40) Colabufo, N. A.; Berardi, F.; Contino, M.; Niso, M.; Abate, C.;
Perrone, R.; Tortorella, V. Antiproliferative and cytotoxic effects
of some σ2 agonists and σ1 antagonists in tumour cell lines. Arch.
Pharmacol. 2004, 370, 106–113.